Session

Overview: Daily adaptive radiotherapy (DART) has recently been supported by relevant technological innovations, and we are now approaching the era of daily adaptation of treatment plans based on a patient's evolving anatomy. While manufacturers advocate widespread adoption of DART, some critics argue that this push is driven by commercial interests rather than robust clinical evidence. In addition, the benefits of the DART should also be assessed while maintaining at least the same quality standards. Potential critical issues for discussion include the challenges of technology implementation, regulatory oversight and the need for guidance. This discussion aims to explore the motivations behind manufacturers' promotion of DART and to review the existing clinical evidence to support its widespread adoption